Morgan Stanley
MAIA icon

Morgan Stanley’s MAIA Biotechnology MAIA Stock Holding History

Morgan Stanley’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
104,017
+90,158
+651% +$120K ﹤0.01% 6078
2026
Q1 		$19.4K Buy
13,859
+12,859
+1,286% +$23.7K ﹤0.01% 6740
2025
Q4 		$1.53K Buy
1,000
+168
+20% +$219 ﹤0.01% 7294
2025
Q3 		$1.28K Sell
832
-4,263
-84% -$6.96K ﹤0.01% 7371
2025
Q2 		$9.17K Hold
5,095
– – ﹤0.01% 6875
2025
Q1 		$7.79K Hold
5,095
– – ﹤0.01% 6876
2024
Q4 		$10.1K Hold
5,095
– – ﹤0.01% 6795
2024
Q3 		$14.3K Hold
5,095
– – ﹤0.01% 6608
2024
Q2 		$17.4K Sell
5,095
-5,000
-50% -$15.8K ﹤0.01% 6511
2024
Q1 		$22.2K Buy
10,095
+5,000
+98% +$7.5K ﹤0.01% 6459
2023
Q4 		$5.96K Hold
5,095
– – ﹤0.01% 6792
2023
Q3 		$11.2K Buy
+5,095
New +$10.1K ﹤0.01% 6694

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley's MAIA Position: Q2 2026 in Review

Morgan Stanley increased its MAIA Biotechnology (MAIA) stake by 651% in Q2 2026, buying an estimated $120K and bringing the position to 104,017 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #6078.

Morgan Stanley first reported a position in MAIA in Q3 2023 and has held it in 12 quarters since. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • Morgan Stanley held 104,017 shares of MAIA Biotechnology worth $150K as of Q2 2026.
  • Morgan Stanley bought 90,158 MAIA Biotechnology shares in Q2 2026, an estimated $120K.
  • MAIA Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6078 holding.
  • Morgan Stanley first reported a position in MAIA Biotechnology in Q3 2023 and has held it in 12 quarters since.
  • 36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.